How the unfolding of notable infringement claim could alter commercial approaches for players in wider CBD treatment field.
David Knight
Advertisement
Articles by David Knight
Advertisement
Latest Updated Articles
Commercializing Cannabis and Patent LitigationFebruary 10th 2021
Advertisement
Advertisement
Trending on PharmExec
1
Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline
2
What the Peptide Advisory Vote Actually Means: Q&A with James LaValle
3
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
4
Focusing on Asset Acquisition Over Building a Single Platform Technology
5